

Daniel Catovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9589433/publications.pdf>

Version: 2024-02-01

89
papers

6,002
citations

117625

34
h-index

79698

73
g-index

89
all docs

89
docs citations

89
times ranked

5552
citing authors

#	ARTICLE	IF	CITATIONS
1	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	1.4	1,069
2	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. <i>Lancet</i> , The, 2007, 370, 230-239.	13.7	660
3	The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. <i>International Journal of Cancer</i> , 1982, 30, 257-264.	5.1	578
4	Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b). <i>American Journal of Clinical Pathology</i> , 1997, 108, 378-382.	0.7	336
5	Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2223-2229.	1.6	235
6	Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. <i>British Journal of Haematology</i> , 2009, 145, 733-740.	2.5	229
7	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
8	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. <i>Blood</i> , 2013, 121, 468-475.	1.4	190
9	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	21.4	166
10	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 1986, 63, 377-387.	2.5	159
11	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. <i>Haematologica</i> , 2010, 95, 1705-1712.	3.5	116
12	Long remissions in hairy cell leukemia with purine analogs. <i>Cancer</i> , 2005, 104, 2442-2448.	4.1	109
13	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 1987, 65, 23-29.	2.5	99
14	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia.. <i>British Journal of Haematology</i> , 1986, 64, 77-86.	2.5	90
15	Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2319-2326.	1.4	90
16	Polyclonal integration of HTLV-I proviral DNA in lymphocytes from HTLV-I seropositive individuals: an intermediate state between the healthy carrier state and smouldering ATL. <i>British Journal of Haematology</i> , 1988, 68, 169-174.	2.5	79
17	The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia. <i>British Journal of Haematology</i> , 1988, 69, 205-211.	2.5	76
18	Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. <i>British Journal of Haematology</i> , 2012, 156, 186-195.	2.5	76

#	ARTICLE	IF	CITATIONS
19	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	12.8	75
20	Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 322-328.	2.5	69
21	ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. <i>Haematologica</i> , 2014, 99, 736-742.	3.5	69
22	Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 21-24.	1.3	65
23	Two new cell lines from B-prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. <i>International Journal of Cancer</i> , 1986, 38, 531-538.	5.1	64
24	Îµ-Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2124-2132.	4.1	63
25	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. <i>Cell Reports</i> , 2016, 16, 2061-2067.	6.4	58
26	Long-term follow-up after purine analogue therapy in hairy cell leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 217-229.	1.7	57
27	The clinical significance of patients' sex in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 1088-1094.	3.5	55
28	Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. <i>Leukemia and Lymphoma</i> , 2011, 52, 75-78.	1.3	53
29	Histological Study of Bone Marrow Regeneration following Chemotherapy for Acute Myeloid Leukaemia and Chronic Granulocytic Leukaemia in Blast Transformation. <i>British Journal of Haematology</i> , 1980, 45, 535-540.	2.5	48
30	Blast Crisis of Chronic Granulocytic Leukemia with Mast Cell and Basophilic Precursors. <i>American Journal of Clinical Pathology</i> , 1985, 83, 254-259.	0.7	48
31	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. <i>Leukemia and Lymphoma</i> , 2008, 49, 2108-2115.	1.3	48
32	CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. <i>The Hematology Journal</i> , 2004, 5, 145-151.	1.4	47
33	The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. <i>Cancer</i> , 2007, 110, 2240-2247.	4.1	47
34	Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. <i>British Journal of Haematology</i> , 2008, 143, 690-697.	2.5	45
35	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	6.2	40
36	Chlorambucil "Still Not Bad: A Reappraisal. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S2-S6.	0.4	35

#	ARTICLE	IF	CITATIONS
37	Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. <i>Leukemia</i> , 2020, 34, 1760-1774.	7.2	34
38	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. <i>Scientific Reports</i> , 2017, 7, 41071.	3.3	31
39	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	1.4	30
40	The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. <i>British Journal of Haematology</i> , 2016, 174, 767-775.	2.5	29
41	Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 1289-1298.	1.3	28
42	Cytochrome P450 Allele <i>CYP3A7*1C</i> Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. <i>Cancer Research</i> , 2016, 76, 1485-1493.	0.9	28
43	Early Results from LRF CLL4: A UK Multicenter Randomized Trial.. <i>Blood</i> , 2005, 106, 716-716.	1.4	27
44	Haematological Reconstitution after Autografting for Chronic Granulocytic Leukaemia in Transformation: the Influence of Previous Splenectomy. <i>British Journal of Haematology</i> , 1980, 45, 223-231.	2.5	26
45	Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. <i>Blood Advances</i> , 2019, 3, 2474-2481.	5.2	25
46	Prognostic Factors in the UK LRF CLL4 Trial.. <i>Blood</i> , 2005, 106, 2099-2099.	1.4	20
47	Cytochemistry of Normal Lymphocyte Subsets Defined by Monoclonal Antibodies and Immunocolloidal Gold. <i>Scandinavian Journal of Haematology</i> , 1983, 30, 433-443.	0.0	18
48	Response to Therapy and Survival in CLL Is Influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial.. <i>Blood</i> , 2004, 104, 13-13.	1.4	18
49	Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.. <i>Blood</i> , 2008, 112, 2101-2101.	1.4	15
50	CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. <i>Haematologica</i> , 2013, 98, 274-278.	3.5	14
51	Prognostic Factors in the UK LRF CLL4 Trial.. <i>Blood</i> , 2006, 108, 299-299.	1.4	14
52	Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.. <i>Blood</i> , 2005, 106, 922-922.	1.4	13
53	Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin. <i>European Journal of Haematology</i> , 2009, 40, 185-187.	2.2	12
54	The long-term outcome of patients in the LRF CLL 4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. <i>British Journal of Haematology</i> , 2016, 172, 228-237.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Prolymphocytic leukaemia: surface morphology in 21 cases as seen by scanning electron microscopy and comparison with B-type CLL and CLL in "prolymphocytoid"™ transformation. British Journal of Haematology, 1984, 57, 577-584.	2.5	8
56	The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. Leukemia, 2021, 35, 2563-2569.	7.2	8
57	An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy. British Journal of Haematology, 2015, 171, 784-787.	2.5	7
58	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood Advances, 2022, 6, 4224-4227.	5.2	7
59	Current treatment of hairy cell leukaemia. European Journal of Haematology, 1988, 41, 193-196.	2.2	6
60	Evaluation of serum markers in the LRF CLL4 trial: β_2 -microglobulin but not serum free light chains, is an independent marker of overall survival. Leukemia and Lymphoma, 2016, 57, 2342-2350.	1.3	5
61	Quality of Life in the LRF CLL4 Trial.. Blood, 2005, 106, 2111-2111.	1.4	5
62	The effect of tetradecanoyl Δ 12, 13 Δ phorbol acetate on "hairy"™ cells. Scandinavian Journal of Haematology, 1984, 33, 301-308.	0.0	4
63	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia, 2022, 36, 271-274.	7.2	4
64	Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.. Blood, 2004, 104, 957-957.	1.4	4
65	The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.. Blood, 2006, 108, 304-304.	1.4	3
66	The changing face of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 2283-2284.	1.3	2
67	The Clinical Presentation of CLL. Hematologic Malignancies, 2019, , 39-50.	0.2	2
68	Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL). Blood, 2011, 118, 4986-4986.	1.4	2
69	Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia - response to Benzetin. British Journal of Haematology, 2010, 148, 665-666.	2.5	1
70	ZAP-70 Expression in Chronic Lymphocytic Leukemia: Correlation with Clinical and Biological Features.. Blood, 2004, 104, 1915-1915.	1.4	1
71	Drug Sensitivity by TRAC (DiSC) Assay as a Prognostic Factor for Patient Response in Untreated CLL: Results from the UK LRF CLL4 Trial.. Blood, 2006, 108, 303-303.	1.4	1
72	Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial.. Blood, 2011, 118, 3884-3884.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Familial multiple myeloma. <i>Haematologica</i> , 2005, 90, 3-4.	3.5	1
74	B-cell prolymphocytic leukemia and hairy cell leukemia: new advances in biology and treatment. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 159-167.	1.6	0
75	B- Prolymphocytic Leukemia Shows Heterogeneous IgVH Mutational Status and Expression of ZAP-70 and CD38.. <i>Blood</i> , 2004, 104, 2004-2004.	1.4	0
76	Gene Expression Reveals Two Distinct Biological Groups within T-Cell Prolymphocytic Leukaemia.. <i>Blood</i> , 2005, 106, 4366-4366.	1.4	0
77	Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v).. <i>Blood</i> , 2005, 106, 4997-4997.	1.4	0
78	B-Cell Prolymphocytic Leukemia (B-PLL) and Chronic Lymphocytic Leukemia (CLL) Express Distinct Genomic Profiles.. <i>Blood</i> , 2005, 106, 4372-4372.	1.4	0
79	Combinations of ZAP-70, CD38 and IgVH Mutational Status as Predictors of Time to First Treatment in CLL.. <i>Blood</i> , 2005, 106, 711-711.	1.4	0
80	B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richterâ€™s Syndrome.. <i>Blood</i> , 2005, 106, 4999-4999.	1.4	0
81	Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.. <i>Blood</i> , 2007, 110, 2062-2062.	1.4	0
82	Disease Burden of Chronic Lymphocytic Leukemia within the European Union.. <i>Blood</i> , 2007, 110, 5151-5151.	1.4	0
83	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant. <i>Blood</i> , 2008, 112, 3136-3136.	1.4	0
84	Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study. <i>Blood</i> , 2008, 112, 3140-3140.	1.4	0
85	Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.. <i>Blood</i> , 2009, 114, 3467-3467.	1.4	0
86	The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other â€™Mutatedâ€™ Cases Defined by a 98% Cut off. <i>Blood</i> , 2011, 118, 2842-2842.	1.4	0
87	Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas. <i>Blood</i> , 2012, 120, 3505-3505.	1.4	0
88	ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial. <i>Blood</i> , 2013, 122, 4137-4137.	1.4	0
89	Early clinical trials in chronic lymphocytic leukaemia in the UK. <i>British Journal of Haematology</i> , 2020, 191, 535-541.	2.5	0